Real-World study checks OZURDEX safety in chinese DME patients
NCT ID NCT06548568
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study follows 110 adults with diabetic macular edema who are prescribed OZURDEX (a dexamethasone implant placed in the eye) by their doctors in routine Chinese clinics. Researchers will track side effects like cataracts, high eye pressure, and bleeding over two years. The goal is to see how safe the drug is in real-world use, not to test a new treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dexamethasone intravitreal implant (OZURDEX)
What this could lead to
If successful, this study will confirm that OZURDEX is safe for long-term use in Chinese patients with diabetic macular edema in everyday practice.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by other factors. It only tracks safety, not whether the drug works better than alternatives.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC MACULAR EDEMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
General Hospital of Central Theater Command /ID# 273618
Wuhan, Hubei, 430000, China
-
Henan Provincial Eye Hosptial /ID# 272424
Zhengzhou, Henan, 450003, China
-
Peking University People'S Hospital /ID# 274505
Beijing, Beijing Municipality, 100034, China
-
Qingdao Eye Hospital Of Shandong First Medical University /ID# 268173
Qingdao, Shandong, 266071, China
-
Shanghai General hospital /ID# 270376
Shanghai, Shanghai Municipality, 200080, China
-
Shanxi Eye Hospital /ID# 270564
Taiyuan, 030072, China
-
The Affiliated Eye Hospital Of Wenzhou Medical University /ID# 274466
Wenzhou, Zhejiang, 325027, China
-
The First Affiliated Hospital of Dalian Medical University /ID# 270563
Dalian, Liaoning, 116000, China
-
The Second Affiliated Hospital of Zhejiang University School of Medicine /ID# 273617
Hangzhou, Zhejiang, 310009, China
-
West China Hospital of Sichuan University /ID# 273656
Chengdu, Sichuan, 610041, China
-
Xi'an Fourth Hospital /ID# 270562
Xi'an, Shaanxi, 710004, China
-
Xiamen Eye Center of Xiamen University /ID# 268172
Xiamen, Fujian, 390000, China
-
Zhongshan Ophthalmic Center,SunYat-Sen University /ID# 274555
Guangzhou, Guangdong, 510623, China